Time evolution of cytokine profiles associated with mortality in COVID-19 hospitalized patients.

Autor:	Sánchez-de Prada L; BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.; Microbiology and Immunology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Gorgojo-Galindo Ó; BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.; Department of Surgery, Faculty of Medicine, Universidad de Valladolid, Valladolid, Spain., Fierro I; Faculty of Health Science, Universidad Europea Miguel de Cervantes, Valladolid, Spain., Martínez-García AM; Microbiology and Immunology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., de Quintana GS; Anesthesiology and Critical Care Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Gutiérrez-Bustillo R; BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.; Anesthesiology and Critical Care Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Pelaez-Jareño MT; Anesthesiology and Critical Care Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Álvarez-Fuente E; Anesthesiology and Critical Care Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Gómez-Sánchez E; BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.; Department of Surgery, Faculty of Medicine, Universidad de Valladolid, Valladolid, Spain.; Anesthesiology and Critical Care Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Tamayo E; BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.; Department of Surgery, Faculty of Medicine, Universidad de Valladolid, Valladolid, Spain.; Anesthesiology and Critical Care Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain., Tamayo-Velasco Á; BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.; Haematology and Hemotherapy Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Martín-Fernández M; BioCritic, Group for Biomedical Research in Critical Care Medicine, Valladolid, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.; Department of Medicine, Faculty of Medicine, Universidad de Valladolid, Valladolid, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2022 Sep 27; Vol. 13, pp. 946730. Date of Electronic Publication: 2022 Sep 27 (Print Publication: 2022).
DOI:	10.3389/fimmu.2022.946730
Abstrakt:	Background: High cytokine levels have been associated with severe COVID-19 disease. Although many cytokine studies have been performed, not many of them include combinatorial analysis of cytokine profiles through time. In this study we investigate the association of certain cytokine profiles and its evolution, and mortality in SARS-CoV2 infection in hospitalized patients. Methods: Serum concentration of 45 cytokines was determined in 28 controls at day of admission and in 108 patients with COVID-19 disease at first, third and sixth day of admission. A principal component analysis (PCA) was performed to characterize cytokine profiles through time associated with mortality and survival in hospitalized patients. Results: At day of admission non-survivors present significantly higher levels of IL-1α and VEGFA (PC3) but not through follow up. However, the combination of HGF, MCP-1, IL-18, eotaxine, and SCF (PC2) are significantly higher in non-survivors at all three time-points presenting an increased trend in this group through time. On the other hand, BDNF, IL-12 and IL-15 (PC1) are significantly reduced in non-survivors at all time points with a decreasing trend through time, though a protective factor. The combined mortality prediction accuracy of PC3 at day 1 and PC1 and PC2 at day 6 is 89.00% (p<0.001). Conclusions: Hypercytokinemia is a hallmark of COVID-19 but relevant differences between survivors and non-survivors can be early observed. Combinatorial analysis of serum cytokines and chemokines can contribute to mortality risk assessment and optimize therapeutic strategies. Three clusters of cytokines have been identified as independent markers or risk factors of COVID mortality. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Sánchez-de Prada, Gorgojo-Galindo, Fierro, Martínez-García, de Quintana, Gutiérrez-Bustillo, Pelaez-Jareño, Álvarez-Fuente, Gómez-Sánchez, Tamayo, Tamayo-Velasco and Martín-Fernández.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu